Omar Khwaja is head of research and development and chief medical officer at VectivBio, a clinical-stage biotechnology company focused on the discovery and development of innovative treatments for patients with severe rare diseases. Before joining VectivBio, Dr. Khwaja was CMO and head of R&D at Voyager Therapeutics, a neuroscience gene therapy biotechnology company. Dr. Khwaja was previously global head of rare diseases and global head of neuroscience translational medicine and vice president of pharmaceutical research and early development at Roche.
He joined Roche from the staff of the Department of Neurology at Boston Children’s Hospital and the Faculty of Harvard Medical School. At Harvard, Dr. Khwaja led a translational neuroscience research group focused on translational medicine in children. He was also an attending physician in neurogenetics, fetal-neonatal neurology, and critical care neurology at Boston Children’s Hospital where he directed the Neurogenetics Program.
Dr. Khwaja completed his neurology training at Massachusetts General Hospital and Boston Children’s Hospital where he became Chief Resident and went on to complete a fellowship in critical care and fetal-neonatal neurology. He received his M.D. and Ph.D. from the University of Cambridge before training in pediatrics and clinical genetics at the Royal London Hospital, Great Ormond Street Hospital, and the Royal Children’s Hospital, Melbourne.
Dr. Khwaja is a member of the Royal College of Physicians and currently also serves as honorary consultant neurologist at the Royal London Hospital. Dr. Khwaja is also chief medical officer of the Spinal Muscular Atrophy Foundation, chair of the scientific advisory board of the CDKL5 Forum and sits on the advisory board of Pureos Bioventures, a life sciences venture capital firm focused on next-generation therapeutics.